Detalhe da pesquisa
1.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet
; 403(10421): 31-43, 2024 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048793
2.
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Breast Cancer Res Treat
; 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38703285
3.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38129136
4.
Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy.
Int J Gynecol Cancer
; 2023 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38054270
5.
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.
Oncologist
; 27(7): e561-e570, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278078
6.
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
BMC Cancer
; 22(1): 1150, 2022 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36348385
7.
Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.
Proc Natl Acad Sci U S A
; 116(9): 3863-3872, 2019 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733293
8.
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 22(5): 609-619, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33845034
9.
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Breast Cancer Res
; 23(1): 21, 2021 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33579347
10.
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Breast Cancer Res Treat
; 186(2): 417-428, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392835
11.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152285
12.
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Breast Cancer Res
; 22(1): 124, 2020 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176887
13.
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Future Oncol
; 16(33): 2763-2778, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781837
14.
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Oncologist
; 24(11): e1024-e1033, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023863
15.
Mirvetuximab soravtansine: an oasis in the desert?
Int J Gynecol Cancer
; 34(4): 478-479, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388176
16.
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Breast J
; 25(2): 219-225, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30734437
17.
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Lancet Oncol
; 19(6): 812-824, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29706375
18.
Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Gynecol Oncol
; 150(3): 471-477, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30060963
19.
Integrating planning perception and action for informed object search.
Cogn Process
; 19(2): 285-296, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28808825
20.
A Passive Learning Sensor Architecture for Multimodal Image Labeling: An Application for Social Robots.
Sensors (Basel)
; 17(2)2017 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28208671